CRISPR Therapeutics AG (CRSP) Depreciation and Depletion (2015 - 2026)

CRISPR Therapeutics AG has disclosed Depreciation and Depletion across 12 years of filings, most recently posting $4.3 million for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $4.3 million, down 8.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.9 million (down 1.05% YoY), and the FY2025 annual result was $19.4 million, up 1.04% from the prior year.
• Depreciation and Depletion came in at $4.3 million for Q1 2026 at CRISPR Therapeutics AG, down from $5.6 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $7.3 million in Q2 2022 to a low of $4.3 million in Q1 2026.
• The 5-year median for Depreciation and Depletion is $4.9 million (2023), against an average of $5.1 million.
• Across the five-year window, Depreciation and Depletion soared 122.22% in 2022 and slumped 31.51% in 2023, its largest moves.
• CRISPR Therapeutics AG's Depreciation and Depletion stood at $5.8 million in 2022, then declined by 15.52% to $4.9 million in 2023, then dropped by 2.04% to $4.8 million in 2024, then grew by 16.67% to $5.6 million in 2025, then retreated by 23.21% to $4.3 million in 2026.
• The last three Depreciation and Depletion figures came in at $4.3 million (Q1 2026), $5.6 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.